CompletedNCT03128021
Antidepressants and Brain Changes in Older Adults With Depression
About this title
Read the official source — NCT03128021Medication studyAges 60+United States
Understand this study
Who was this study for?
Listed age limits: from 60 years.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: May 24, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 57
- Sponsor
- Howard Aizenstein
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 60 Years
- Official registry ID
- NCT03128021
- Official title
Show the full official title
Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Howard Aizenstein.
Did this study involve medication?
Yes. The study involved medication, including Escitalopram Pill and Levomilnacipran Pill.
Who was this study for?
Listed age limits: from 60 years.
